| 注册
首页|期刊导航|神经病学与神经康复学杂志|仑卡奈单抗治疗早发型阿尔茨海默病患者:1例报告及文献复习

仑卡奈单抗治疗早发型阿尔茨海默病患者:1例报告及文献复习

支楠 耿介立 曹雯炜 宋雅颖 王刚

神经病学与神经康复学杂志2025,Vol.21Issue(3):158-166,9.
神经病学与神经康复学杂志2025,Vol.21Issue(3):158-166,9.DOI:10.12022/jnnr.2025-0115

仑卡奈单抗治疗早发型阿尔茨海默病患者:1例报告及文献复习

Lecanemab treatment for early-onset Alzheimer's disease:A case report and literature review

支楠 1耿介立 1曹雯炜 1宋雅颖 1王刚1

作者信息

  • 1. 上海交通大学医学院附属仁济医院神经内科,上海 200127
  • 折叠

摘要

Abstract

Objective:To investigate the clinical effectiveness and safety of lecanemab in patients with early-onset Alzheimer's disease(EOAD),thereby providing a reference for the clinical application of disease-modifying treatment(DMT). Methods:The diagnosis and treatment process of a 54-year-old male patient with EOAD were reported,and the disease modifying effect of lecanemab was analyzed based on clinical manifestations,imaging features,treatment response and relevant literature. Results:After receiving traditional anti-dementia drug treatment,the patient initiated treatment with lecanemab(10 mg/kg body weight,once every 2 weeks)and was followed up for 9 months.Before treatment,the Mini-mental State Examination(MMSE)scale score was 20,Montreal Cognitive Assessment(MoCA)scale score was 12,amyloid β-protein(Aβ)-PET showed a standardized uptake value ratio(SUVR)of 1.325(positive),and the Centiloid value was 51.073.After 9 months of treatment,β-PET indicated a reduction in SUVR to 1.015(below the negative threshold of 1.10)and a decrease of 55.688 units in Centiloid value;Tau-PET showed no further progression of pathological deposits.Clinical assessments revealed improvement of 1 point in MMSE score(to 21 points),and stable scores in MoCA and Boston Naming Test(BNT).No adverse effects,such as cerebral microhemorrhages or edema,were observed during treatment. Conclusion:This case report shows that lecanemab can effectively clear the deposition of Aβ in the brain,delay the pathological progression of Tau protein,improve the function in the patient with EOAD,and has good safety.This case provides clinical evidence for early DMT intervention in EOAD.

关键词

早发型阿尔茨海默病/仑卡奈单抗/疾病修饰治疗/安全性

Key words

Early-onset Alzheimer's disease/Lecanemab/Disease-modifying treatment/Safety

引用本文复制引用

支楠,耿介立,曹雯炜,宋雅颖,王刚..仑卡奈单抗治疗早发型阿尔茨海默病患者:1例报告及文献复习[J].神经病学与神经康复学杂志,2025,21(3):158-166,9.

神经病学与神经康复学杂志

1672-7061

访问量0
|
下载量0
段落导航相关论文